MedTrace Logo

Use of Modafinil in the Treatment of Tinnitus

NCT00591019 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2015-10-08

Study results available
· View outcomes & findings →

Summary

A study on the effects of the FDA approved drug Modafinil upon attention problems associated with tinnitus. This is considered to be a safe drug with few side effects. Each subject will be asked to participate in 3 sessions each lasting approximately 1 hour in which cognitive testing and recordings will be taken. The study involves each subject taking a 2- week supply of Modafinil and a 2- week supply of placebo. We hypothesize inattention related to thalamocortical dysrhythmia found in tinnitus can be reduced by Modafinil thus improving vigilance.

Conditions

  • Tinnitus

Interventions

DRUG

Modafinil

200 mg/day, morning dose

OTHER

Placebo

Sugar pill once per day in the morning.

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • John L Dornhoffer, MD · University of Arkansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE

Eligibility

Min Age
20 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-03-31
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591019 on ClinicalTrials.gov